HF 1020

Drug Profile

HF 1020

Alternative Names: Enterotoxin B; EtxB

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Bristol
  • Developer Trident Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Bacterial proteins; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 10 Sep 2010 Preclinical trials in Inflammation in United Kingdom (unspecified route)
  • 11 Jul 2007 HF 1020 is available for licensing worldwide (http://www.hunter-fleming.com)
  • 11 Jan 2002 Preclinical development for Allergic asthma in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top